Eribulin mesylate, a microtubule dynamics inhibitor, has been approved for the treatment of several malignancies. Due to its novel mechanism of action, eribulin is often associated with a distinct profile of adverse events including hematologic toxicities. Here we searched PubMed and Embase database from reception to August 2017 for clinical trials with eribulin treatment. Eligible studies included trials with eribulin administered at a standard dose of 1.4 mg/m 2 intravenously on days 1 and 8 in a 21-day cycle, and adequate safety data profile reporting neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia. The overall incidence, relative risk (RR) and 95% confidence interval (CI) were calculated. A total of 39 studies with 6,092 subjects were included in this study. The incidences of eribulin related all-grade and high-grade hematologic toxicities were: neutropenia, 56% and 39%; leucopenia, 44% and 21%; anemia, 33% and 2%; febrile neutropenia, 5% and 5%; and thrombocytopenia, 12% and 12%. Compared with controls, eribulin was associated with a significant increased risk of all-grade (RR, 1.94; 95% CI, 1.37-2.74) and high-grade (RR, 2.58; 95% CI, 1.30-5.10) neutropenia, all-grade (RR, 1.81; 95% CI, 1.10-2.97) and high-grade (RR, 2.95; 95% CI, 1.36-6.39) leucopenia, but not with anemia and febrile neutropenia. Trial sequential analysis showed the results from neutropenia, leucopenia and anemia established sufficient and conclusive evidence. Our study suggested that eribulin therapy, compared with control, was associated with an increased risk of hematologic toxicities. Hence hematologic monitoring at regular intervals should be advised.
INTRODUCTION
Eribulin mesylate (hereafter referred as "eribulin"), a macrocyclic ketone analogue of Halichondrin B, is a completely synthetic, microtubule dynamics inhibitor [1, 2] . Unlike traditional tubulin-targeting agents which usually suppress growth and depolymerization of microtubules, eribulin inhibits microtubule polymerization through a special binding site on B-tubulin [3] . Preclinical evidence further reveals that eribulin suppresses the development of tumor by inhibiting mitotic spindle formation [3] , reversing phenotype from epithelial-mesenchymal transition state to mesenchymal-epithelial transition state [4] , and remodeling tumor vasculature [5] . Currently, eribulin has been approved by the US Food and Drug Administration (FDA) for the treatment of breast cancer (BC) [6] , and recently, liposarcoma [7] . Additionally, it is reported that eribulin is being investigated in several malignancies such as non-small cell lung cancer, pancreatic cancer, head and neck cancer, prostate cancer, and ovarian cancer [8] . Accordingly the increase in the application of eribulin is expected in the future. Due to its novel mechanism, eribulin treatment is often associated with a distinct profile of adverse events. Previous studies have showed that the common side effects of eribulin were myelosuppression, fatigue/ asthenia, alopecia, and peripheral neuropathy [9] [10] [11] [12] [13] [14] . Although hematologic toxicities associated with eribulin have been reported, there has been no systematic attempt to synthesize these data and the relative risk of hematologic toxicities induced by eribulin has yet to be evaluated. Therefore, here we conducted a metaanalysis of available clinical data to calculate the overall incidence and relative risk of developing hematologic toxicities, namely neutropenia, leucopenia, anemia, febrile neutropenia, and thrombocytopenia, in cancer patients treated with eribulin.
RESULTS

Search results
A total of 796 potentially relevant articles were found during the initial search, including 395 studies from PubMed and 401 trials from Embase. 361 articles were excluded because of duplications. After careful screening of titles and abstracts, 369 studies were removed since they did not meet the eligible criteria. Further reviewing the whole texts of the remaining 66 potentially eligible articles, 27 were not included because of different dose of eribulin (n = 19) , insufficient data (n = 5) and duplication (n = 3). A total of 39 studies were enrolled for the final analysis. 33 were single arm trials , the other 6 were RCTs [9] [10] [11] [12] [13] [14] . A flow chart was presented in Figure 1 . 6 ,092 patients were included in this meta-analysis (eribulin, 4,958; control, 1, 134 control, 0) from 1 study. The dose and schedule of eribulin was 1.4 mg/m 2 in 2-5 minutes intravenously on days 1 and 8 on a 21-day schedule, the currently FDA-recommended dose until unacceptable toxicity, disease progression or patient refusal. In one study [14] , pharmacokinetic and pharmacodynamical analysis revealed that 0.9 mg/ m 2 is the optimal dose for NSCLC patients. The median treatment ranged from 1.5 months [34] to 7.7 months [23] . The basic clinicopathological characteristics of eligible trials were summarized in Table 1 . The numbers of hematologic toxicities were presented in Table 2 . It should be noted that not all studies consistently illustrated the five adverse event (AE) of our interest.
Population characteristics
Overall incidence of hematological toxicity
A total of 4,958 patients from 39 non-randomized trials and treatment arms in RCTs were included. The overall incidences of all-grade neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia in patients treated with eribulin were 56% (95% CI, 46%-65%), 44% (95% CI, 30%-59%), 33% (95% CI, 25%-40%), 5% (95% CI, 3%-7%) and 12% (95% CI, 8%-15%), respectively (Table 3 ). Whereas the summary incidences of high-grade (grade III and grade IV) neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia were 39% (30%-48%), 21% (95% CI, 14%-28%), 2% (95% CI, 1%-3%), 5% (95% CI, 3%-6%), and 12% (95% CI, 6%-18%), respectively (Table 4 ). Significant heterogeneities were observed in the calculation of these hematological AEs. Therefore, the random-effects models were applied. Since most of these eligible trials were conducted in patients with breast cancer, the hematological toxicities of eribulin stratified by different cancer type were examined ( Table 3 and Table 4 ). The incidences of all-grade (p = 0.76) and highgrade (p = 0.54) neutropenia were similar in BC patients and non-BC patients. Similarly, the incidences of all-grade (p = 0.69) and high-grade (p = 0.38) leucopenia did not show statistical difference between BC patients and non-BC patients. Meanwhile, the incidences of both all-grade (p = 0.004) and high-grade (p = 0.04) anemia in non-BC patients were statistically higher compared with BC patients. In contrast, the incidences of all-grade (p = 0.01) and high-grade (p = 0.02) thrombocytopenia in non-BC patients were lower compared with BC patients.
Relative risk of hematologic adverse events
The RRs and their 95% CIs of hematologic toxicities were calculated with 6 RCTs (3 phase III studies and 3 phase II studies including 2,546 patients) [9] [10] [11] [12] [13] [14] . The relative risks of all-grade neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia were 1.94 (95% CI, 1.37-2.74; p = 0.01), 1.81 (95% CI, 1.10-2.97; p = 0.02), 0.95 (95% CI, 0.82-1.11, p = 0.53), 2.15 (95% CI, 0.79-5.82; p = 0.12), and 0.21 (95% CI, 0.12-0.36; p < 0.001) respectively ( Figure 2 ). The relative risk of high-grade neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia in patients treated with eribulin were 2.58 (95% CI, 1.30-5.10; p = 0.02), 2.95 (95% CI, 1.36-6.39; p = 0.01), 0.77 (95% CI, 0.52-1.14; p = 0.19), 2.15 (95% CI, 0.79-5.82; p = 0.12), and 0.03 (95% CI, 0.00-0.21; p < 0.001) respectively ( Figure 3 ). The fixed-effects models were applied in the analysis of both all-grade and high-grade anemia, febrile neutropenia, and thrombocytopenia because there was no evidence of heterogeneity for these outcomes. Additional analyses using the random-effects models yielded similar results. Substantial heterogeneities were observed in RR calculation of all-grade and high-grade neutropenia and leucopenia. Sensitivity analyses were then carried out to identify potential sources of heterogeneities and to examine the impact of different exclusion criteria on the overall relative risk. Exclusion of one study [11] in which eribulin was compared with capecitabine did not changed the trend of overall risk estimate, but no significant heterogeneities were observed among the remaining trials (as shown in Table 5 ).
Trial sequential analysis (TSA) showed that the cumulative z curve crossed both the conventional boundary and the trial sequential monitoring boundary in neutropenia and leucopenia analysis, crossed the futility boundary and entered the futility area in anemia analysis ( Figure 4 ). Both these cases established sufficient and conclusive evidence. Accordingly, further trials were not request and were unlikely change our conclusion. Because of the limited available data for febrile neutropenia and thrombocytopenia analysis, TSA was not conducted.
Publication bias
Egger's test and Begg's funnel plot were conducted to evaluate the publication bias for RR of both all-grade and high-grade neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia. The shapes of the funnel plots did not show any evidence of obvious asymmetry in all analysis.
DISCUSSION
To our knowledge, this is the first meta-analysis focused on hematologic toxicities associated with eribulin mesylate. Our data revealed that the overall incidences of eribulin related all-grade and high-grade hematologic toxicities were: neutropenia, 56% and 39%; leucopenia, 44% and 21%; anemia, 33% and 2%, febrile neutropenia, 5% and 5%; and thrombocytopenia, 12% and 12%. In addition, our analysis on RCTs revealed that the relative risk of all-grade neutropenia and leucopenia were approximately two-fold (three-fold for high-grade) in patients with eribulin treatment compared with those in the control arms. In contrast, no significantly increased risks were identified in terms of anemia and febrile neutropenia.
Accumulating evidence reveals that eribulin has many characteristics that makes it distinct from other microtubule-targeting agents [48] . Although still not completely clear, the specific biological effects of eribulin might underlie its unique impact on hematologic toxicities. Preclinical studies showed that eribulin decreased the expression of genes related with vascular endothelial growth factor (VEGF), Ephrin-EphR, Wnt, and Notch signaling pathways which were known to be critical in vascular functions [48] . In vitro evidence suggested that eribulin could down-regulate the expression of VEGF, CA9, Notch4, Dll4 and Efnb2 [5, 48] . In clinic, significantly decreased concentration of deoxyhemoglobin was observed in patients treated with eribulin [49] . Eribulin therapy could also decreased the plasma concentration of transforming growth factor beta 1 (TGF-β1), which linked to multiple gene that controlled the growth, proliferation, differentiation and apoptosis of blood cells [50] . Our results were consistent with pre-clinical discoveries and corroborated the theory that eribulin treatment increased the risk of myelosuppression in cancer.
Five types of hematologic toxicities were analyzed in the present study. Interestingly, high incidence rates and risks only occurred in two types of hematologic AEs, neutropenia and leucopenia. The incidence rates and risks of other two types of hematologic toxicities, anemia and febrile neutropenia, did not show significant difference compared with control. The incidences and relative risk of eribulin related thrombocytopenia needed further investigation. These discrepancies might be due to the differences in the mechanisms of action among these hematologic toxicities [48] . Hematologic events were one of the most common adverse events that could lead to therapy adjustment and discontinuation in clinical trials. High-grade neutropenia and leucopenia were often clinically significant and needed careful medical intervention considering these AEs potentially led to hemorrhage and sepsis in patients. In fact, some large RCTs even reported that fatal adverse events occurred because of hematologic toxicities [9, 11, 13] . During eribulin treatment, patients who developed neutropenia and leucopenia were usually managed with dose reduction, treatment delays and granulocyte colonystimulating factor (G-CSF). The application of G-CSF to manage eribulin related high-grade neutropenia was at the physician's choice in accordance with relevant clinical practice guidelines such as European Society for Medical Oncology (ESMO) [51] and European Organization for Research and Treatment of Cancer (EORTC) [52] . It should be noted that neutropenia was reported at a higher incidence in the Asian population than that in the Western patients partly because of the pharmacogenomics [18] .
Since we cannot access to any individual patient data, we did not correlate the risks of infection, bleeding and mortality with neutropenia and leucopenia. Although previous studies reported that poor performance status, advanced age, and low baseline blood cell counts were significant predictors for the severity of neutropenia [53] , there were still no appropriate technique to determine which patients were at high risk of neutropenia and leucopenia. Accordingly, regular monitoring was essential for patients treated with eribulin.
Here we conducted a comprehensive review using the most up-to-date published data, which made our results more extensive. Moreover, with the accumulating evidence and enlarged sample size, we had enhanced the statistical power to provide more precise and reliable estimates. However, our study was restricted by some limitations. First, this was a meta-analysis conducted at the trial level and no clinicopathological variable at the patient level could be analyzed. Second, pooled incidence rates had significant heterogeneities, and this might be due to the different types of underlying malignancies, sample size, insufficient follow-up data among the included trials.
In conclusion, our meta-analysis revealed that eribulin mesylate was associated with an increased risk of hematological toxicities compared with controls. Clinical doctors should be acknowledged of these potential adverse events and hematologic monitoring at regular intervals may be advised.
MATERIALS AND METHODS
The present study was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [54] .
Literature search and study selection
A systematic search of Embase and PubMed database from January 1966 to August 2017 was conducted without any language restrictions. The only search keyword and Medical subject heading used was eribulin. Both inclusion and exclusion criteria were prespecified. To be eligible, published studies had to meet the following criteria: (1) population: non-phase I trials in patients (n > 30) with solid tumor; (2) intervention: eribulin was administered at a standard dose of 1.4 mg/ m 2 in 2-5 minutes intravenously on days 1 and 8 in a 21-day schedule, the currently FDA-recommended dose until unacceptable toxicity, disease progression or patient refusal; (3) clinical outcomes: events or events rates and sample size information for both all-grade and high-grade hematologic toxicities including neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia. Phase I trials were not included because of the small size of patients and various doses in these studies. Other publications on this topic, including review articles, conference abstract, pre-clinical papers, early versions of data later published, editorials, articles not dealing with eribulin were not included (Figure 1 ). Considering recent progress with eribulin had not been published, electronic searches were also carried out in two major international congresses' proceedings (American Society of Clinical Oncology Annual Meeting and European Society of Medical Oncology).When multiple publications of the same study occurred, only the most recent and/or most complete reporting study was included. Any discrepancies were settled by discussion and consensus. Two authors independently conducted the initial search, screened the titles and abstracts, and classified trials as excluded, included and uncertain. Any discrepancy was resolved by consensus.
Data extraction
Eligible abstracts were collected and full texts of relevant articles were checked for the trial design and reporting of hematologic toxicities. The following items were extracted: name of the first author, region, year of publication, underlying malignancy, number of patients enrolled, median age, gender, European cooperative oncology group performance status (ECOG PS), median treatment duration, median overall survival (OS), median progression-free survival (PFS) ( Table 1) , numbers of events of the following AEs (for both all-grade and high-grade): neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia ( Table 2 ). The number of subjects evaluated for toxicity was used as the number analyzed for each study, unless it was indicated otherwise. 
Quality assessment of the eligible studies
Newcastle-Ottawa Scale (NOS) was conducted to assess the methodological quality of all included studies [55] . This scale used a star system to evaluate any study in three sections: selection of participants, comparability of study groups, and the ascertainment of outcomes of interest.
Statistical analysis
The primary analysis examined the overall incidence, relative risk and corresponding 95% CI of allgrade and high-grade hematologic toxicities in cancer patients treated by eribulin. To calculate the incidence, the number of patients receiving eribulin and the number of hematologic toxicities were extracted from the eligible single-arm and randomized controlled trials. The proportion of patients with neutropenia, leucopenia, anemia, febrile neutropenia and thrombocytopenia and 95% CIs were derived from each trial. We calculated RRs and their CIs with data extracted from RCTs only, comparing the incidence of each adverse event in patients assigned to eribulin arms with patients in placebo or control arms. Statistical heterogeneity between different trials or subgroups was evaluated by Cochrane's Q statistic. The I 2 statistic was calculated to assess the extent of inconsistency contributable to the heterogeneity across different studies [56] . The assumption of homogeneity was considered invalid for I 2 > 25% or p < 0.05. Summary RRs and incidences were calculated using fixed-effects or random-effects models depending on the heterogeneity of included trials. Potential publication bias was assessed by visual inspection of a funnel plot, and also evaluated using the tests of Egger et al. [57] and Begg et al. [58] . Twosided p < 0.05 were considered statistically significant. All analysis was performed using Stata version 12.0 (StataCorp, USA).
Trial sequential analysis
Random errors increase the risk of type I error (false-positive results) in meta-analysis because of sparse data and/or repetitive examining [59, 60] . As a result, trial sequential monitoring boundaries, namely trial sequential analysis (TSA), were conducted [59, 61, 62] . It can determine whether the data in any meta-analysis is reliable and conclusive. When the cumulative z curve crosses the trial sequential monitoring boundary or enters the futility area, a sufficient level of evidence for the anticipated intervention effect may have been reached and no further trials are needed. If the z curve crosses none of the boundaries and the required information size has not been reached, there is insufficient evidence to reach a conclusion. Here, we estimated the required information size using α = 0.05 (two-sided), β = 0.20 (power of 80% 
